Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 3/20 | 0.52 |
| ▸ | PPARA | Q07869 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | LMNA | P02545 | 3/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.51 |
| ▸ | RECQL | P46063 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 3/20 | 0.51 |
| ▸ | RAB9A | P51151 | 3/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.40 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.40 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2717815 | 0.87 | ALDH1A1 (0.50) | PPARGPPARAALDH1A1LMNAMAPT | |
| SCHEMBL2718896 | 0.87 | KMT2A (0.47) | PPARGPPARAALDH1A1LMNAMAPT | |
| SCHEMBL4683444 | 0.86 | ALDH1A1 (0.49) | PPARGPPARAALDH1A1LMNAMAPT | |
| SCHEMBL2723083 | 0.85 | PPARG (0.57) | PPARGPPARAALDH1A1LMNAMAPT | |
| SCHEMBL30543408 | 0.83 | ALDH1A1 (0.47) | PPARGPPARAALDH1A1LMNAMAPT | |
| SCHEMBL10151429 | 0.82 | NPC1 (0.56) | PPARGPPARAALDH1A1LMNAMAPT | |
| SCHEMBL2718626 | 0.82 | MAPT (0.77) | PPARGPPARAALDH1A1LMNAMAPT | |
| SCHEMBL2719704 | 0.80 | ALDH1A1 (0.51) | PPARGPPARAALDH1A1LMNAMAPT | |
| SCHEMBL2718628 | 0.79 | ALDH1A1 (0.55) | PPARGPPARAALDH1A1LMNAMAPT | |
| SCHEMBL2720808 | 0.78 | PPARG (0.64) | PPARGPPARAALDH1A1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1647546-B1 | NOVEL HETEROARYL DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO (JP) | 2012-05-02 | — | — | EP | disclosed |
| EP-1647546-B1 | NOVEL HETEROARYL DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO (JP) | 2012-05-02 | — | — | EP | disclosed |
| US-20110212892-A1 | AGENT FOR TREATMENT OF DIABETES | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2011-09-01 | — | — | US | disclosed |
| US-20110212892-A1 | AGENT FOR TREATMENT OF DIABETES | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2011-09-01 | — | — | US | disclosed |
| US-20110212892-A1 | AGENT FOR TREATMENT OF DIABETES | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2011-09-01 | — | — | US | disclosed |
| EP-2351563-A1 | AGENT FOR TREATMENT OF DIABETES | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2011-08-03 | — | — | EP | disclosed |
| US-20080306275-A1 | NOVEL HETEROARYL DERIVATIVE | DANIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2008-12-11 | — | — | US | disclosed |
| US-20080306275-A1 | NOVEL HETEROARYL DERIVATIVE | DANIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2008-12-11 | — | — | US | disclosed |
| US-20080306275-A1 | NOVEL HETEROARYL DERIVATIVE | DANIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2008-12-11 | — | — | US | disclosed |
| US-7425642-B2 | Heteroaryl derivative | DAINIPPON SUMITOMO PHARMA CO. ,LTD. (JP) | 2008-09-16 | — | — | US | disclosed |
| US-7425642-B2 | Heteroaryl derivative | DAINIPPON SUMITOMO PHARMA CO. ,LTD. (JP) | 2008-09-16 | — | — | US | disclosed |
| EP-1386913-B1 | PYRROLE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO (JP) | 2008-07-16 | — | — | EP | disclosed |
| EP-1386913-B1 | PYRROLE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO (JP) | 2008-07-16 | — | — | EP | disclosed |
| US-7220773-B2 | Heterocylic amines used as antidiabetic or hyperglycemic agents | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-05-22 | — | — | US | disclosed |
| US-7220773-B2 | Heterocylic amines used as antidiabetic or hyperglycemic agents | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-05-22 | — | — | US | disclosed |
| US-7220773-B2 | Heterocylic amines used as antidiabetic or hyperglycemic agents | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-05-22 | — | — | US | disclosed |
| US-20060194857-A1 | Novel heteroaryl derivative | DAINIPPON SUMITOMO PHARMA CO. LTD. (JP) | 2006-08-31 | — | — | US | disclosed |
| EP-1647546-A1 | NOVEL HETEROARYL DERIVATIVE | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2006-04-19 | — | — | EP | disclosed |
| US-20040162331-A1 | Pyrrole derivative | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2004-08-19 | — | — | US | disclosed |
| EP-1386913-A1 | PYRROLE DERIVATIVE | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2004-02-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212892-A1 | AGENT FOR TREATMENT OF DIABETES | SLC5A1, GLP1R, SLC5A2 | PPARG 62/4885PPARA 16/4885ALDH1A1 291/4885 |
| US-20060194857-A1 | Novel heteroaryl derivative | NR0B1, UGT1A10, NR0B2 | PPARG 282/4885PPARA 411/4885ALDH1A1 552/4885 |
| US-20080306275-A1 | NOVEL HETEROARYL DERIVATIVE | NR0B1, UGT1A10, NR0B2 | PPARG 282/4885PPARA 411/4885ALDH1A1 552/4885 |
| US-20040162331-A1 | Pyrrole derivative | SLC5A1, GLP1R, SLC5A2 | PPARG 126/4885PPARA 31/4885ALDH1A1 548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.